The price of Moderna Inc. (NASDAQ:MRNA) shares last traded on Wall Street fell -4.47% to $131.59.
Based on available information, 23 analysts follow Moderna Inc. (NASDAQ:MRNA). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $430.00 and a low of $93.00, we find $208.00. Given the previous closing price of $137.75, this indicates a potential upside of 51.0 percent. MRNA stock price is now -7.54% away from the 50-day moving average and -15.28% away from the 200-day moving average. The market capitalization of the company currently stands at $49.80B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Among analysts, 9 rate the stock a hold while 10 rate it a buy. Brokers who have rated the stock have averaged $216.00 as their price target over the next twelve months.
In other news, Bancel Stephane, Chief Executive Officer sold 40,000 shares of the company’s stock on May 18. The stock was sold for $4,950,999 at an average price of $123.77. Upon completion of the transaction, the Chief Executive Officer now directly owns 5,411,946 shares in the company, valued at $712.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 17, Chief Executive Officer Bancel Stephane sold 40,000 shares of the business’s stock. A total of $5,012,648 was realized by selling the stock at an average price of $125.32. This leaves the insider owning 5,411,946 shares of the company worth $712.16 million. Insiders disposed of 4,259,847 shares of company stock worth roughly $560.55 million over the past 1 year. A total of 2.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MRNA stock. A new stake in Moderna Inc. shares was purchased by OFI INVEST ASSET MANAGEMENT during the first quarter worth $2,820,520,000. CAPITAL INTERNATIONAL INVESTORS invested $178,407,000 in shares of MRNA during the first quarter. In the first quarter, GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC acquired a new stake in Moderna Inc. valued at approximately $19,975,000. TREXQUANT INVESTMENT LP acquired a new stake in MRNA for approximately $17,710,000. ABEILLE ASSET MANAGEMENT SA purchased a new stake in MRNA valued at around $12,118,000 in the second quarter. In total, there are 1,538 active investors with 65.90% ownership of the company’s stock.
During the past 12 months, Moderna Inc. has had a low of $115.03 and a high of $217.25. As of last week, the company has a debt-to-equity ratio of 0.05, a current ratio of 3.50, and a quick ratio of 3.30. The fifty day moving average price for MRNA is $141.92 and a two-hundred day moving average price translates $155.08 for the stock.
The latest earnings results from Moderna Inc. (NASDAQ: MRNA) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at $0.18, beating analysts’ expectations of -$1.64 by 1.82. This compares to $8.58 EPS in the same period last year. The net profit margin was 31.80% and return on equity was 25.90% for MRNA. The company reported revenue of $1.86 billion for the quarter, compared to $6.07 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -69.3 percent. For the current quarter, analysts expect MRNA to generate $361.92M in revenue.
Moderna Inc.(MRNA) Company Profile
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Leave a Reply